

March 3, 2017

Pharmacy Announcement

Preferred Drug List (PDL) Changes Effective March 1, 2017

On December 8, 2016, the Pharmacy and Therapeutics (P&T) committee of the Nevada Department of Health and Human Services' Division of Health Care Financing and Policy met to review new and existing therapeutic drug classes on the Nevada Medicaid Preferred Drug List (PDL).

The actions taken by the committee are indicated below. All changes are effective March 1, 2017. The complete PDL is posted on the "[Preferred Drug List](#)" webpage.

Drug Class	Drugs Added as Preferred	Drugs Added as Non-Preferred
Biologic Response Modifiers: Immunomodulators – Targeted Immunomodulators <i>(New)</i>	Cimzia® Cosentyx® Kineret® Orencia® Otezla® Simponi® Xeljanz®	Entyvio® Ilaris® Inflectra® Stelara® Taltz®
Cardiovascular Agents: Antihypertensive Agents – Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)		Qbrelis®
Gastrointestinal Agents: Functional Gastro-Intestinal Disorder Drugs <i>(New)</i>	Amitiza® Linzess®	Movantik® Relistor®
Hormones and Hormone Modifiers: Antidiabetic Agents - Sodium-Glucose Co- Transporter 2 (SGLT2) Inhibitors		Invokamet® XR
Musculoskeletal Agents: Antigout Agents	Colchicine Tab/Cap Probenecid Probenecid/Colchicine Uloric®	Colcrys® Tab Mitigare® Cap Zurampic® Zyloprim®
Otic Agents: Otic Anti- infectives – Otic Quinolones	Cipro HC® Otic Susp	Ciprofloxacin Sol Cetraxal® Otovel®
Psychotropic Agents: Anxiolytics, Sedatives and Hypnotics	Zaleplon Zolpimist®	